{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T18:01:44Z","timestamp":1780596104925,"version":"3.54.1"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.prp.2024.155773","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T17:15:00Z","timestamp":1734023700000},"page":"155773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Enhancing the detection of clinically relevant biomarkers in advanced uterine and tubo-ovarian carcinomas through genome-wide analysis"],"prefix":"10.1016","volume":"266","author":[{"given":"Majd","family":"Al Assaad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Hadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangling","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max F.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyothi","family":"Manohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sigouros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sboner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloise","family":"Chapman-Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Elemento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Holcomb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baris","family":"Boyraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Miguel","family":"Mosquera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2024.155773_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.prp.2024.155773_bib2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","article-title":"Ovarian Cancer, Version 2.2020, NCCN clinical practice guidelines in oncology","volume":"19","author":"Armstrong","year":"2021","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"10.1016\/j.prp.2024.155773_bib3","article-title":"Epithelial Ovarian Cancer. StatPearls, StatPearls Publishing Copyright \u00a9 2024, StatPearls Publishing LLC","author":"Arora","year":"2024","journal-title":"Treasure Isl. (FL)"},{"key":"10.1016\/j.prp.2024.155773_bib4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/IGC.0000000000000843","volume":"27","author":"Gadducci","year":"2017","journal-title":"Int J. Gynecol. Cancer"},{"key":"10.1016\/j.prp.2024.155773_bib5","doi-asserted-by":"crossref","unstructured":"Comprehensive molecular portraits of human breast tumours. Nature 490 (2012) 61-70.","DOI":"10.1038\/nature11412"},{"key":"10.1016\/j.prp.2024.155773_bib6","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/path.5034","article-title":"The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses","volume":"244","author":"McAlpine","year":"2018","journal-title":"J. Pathol."},{"key":"10.1016\/j.prp.2024.155773_bib7","doi-asserted-by":"crossref","first-page":"6422","DOI":"10.1158\/1078-0432.CCR-05-0508","article-title":"Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer","volume":"11","author":"Zorn","year":"2005","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.prp.2024.155773_bib8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/PGP.0000000000000585","article-title":"Molecular classification and emerging targeted therapy in endometrial cancer","volume":"39","author":"Yen","year":"2020","journal-title":"Int J. Gynecol. Pathol."},{"key":"10.1016\/j.prp.2024.155773_bib9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.cll.2023.08.004","article-title":"Molecular pathology of ovarian epithelial neoplasms: predictive, prognostic, and emerging biomarkers","volume":"44","author":"Ordulu","year":"2024","journal-title":"Clin. Lab Med"},{"key":"10.1016\/j.prp.2024.155773_bib10","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial cancer","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.prp.2024.155773_bib11","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1158\/1078-0432.CCR-20-1268","article-title":"Endometrial cancer molecular risk stratification is equally prognostic for endometrioid ovarian carcinoma","volume":"26","author":"Kr\u00e4mer","year":"2020","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.prp.2024.155773_bib12","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/COC.0000000000001024","article-title":"PARP inhibitors in newly diagnosed and recurrent ovarian cancer","volume":"46","author":"Giannini","year":"2023","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.prp.2024.155773_bib13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2174\/1574892813666171204094822","article-title":"PARP inhibitors in epithelial ovarian cancer","volume":"13","author":"Taylor","year":"2018","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.prp.2024.155773_bib14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/bcr3670","article-title":"Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers","volume":"16","author":"Watkins","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.prp.2024.155773_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118434","article-title":"Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy","volume":"261","author":"Gou","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.prp.2024.155773_bib16","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1158\/1535-7163.MCT-21-0873","article-title":"Targeting therapeutic resistance and multinucleate giant cells in CCNE1-amplified HR-proficient ovarian cancer","volume":"21","author":"Bai","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.prp.2024.155773_bib17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1158\/0008-5472.CAN-13-2541","article-title":"Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1\/2 inhibitor sensitivity","volume":"74","author":"Bajrami","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.prp.2024.155773_bib18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/oncolo\/oyab053","article-title":"Homologous recombination deficiency: concepts, definitions, and assays","volume":"27","author":"Stewart","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.prp.2024.155773_bib19","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41698-022-00339-8","article-title":"Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer","volume":"6","author":"Perez-Villatoro","year":"2022","journal-title":"NPJ Precis Oncol."},{"key":"10.1016\/j.prp.2024.155773_bib20","doi-asserted-by":"crossref","first-page":"12880","DOI":"10.1038\/s41598-021-91974-x","article-title":"Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer","volume":"11","author":"Dedeurwaerdere","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2024.155773_bib21","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","article-title":"Tumor mutational burden as a predictive biomarker in solid tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.prp.2024.155773_bib22","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/gcc.22733","article-title":"Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions","volume":"58","author":"Stenzinger","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.prp.2024.155773_bib23","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jmoldx.2024.05.002","article-title":"Recommendations for tumor mutational burden assay validation and reporting: a joint consensus recommendation of the Association for Molecular Pathology, College of American Pathologists, and Society for Immunotherapy of Cancer","volume":"26","author":"Furtado","year":"2024","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.prp.2024.155773_bib24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41436-019-0618-7","article-title":"The complete costs of genome sequencing: a microcosting study in cancer and rare diseases from a single center in the United Kingdom","volume":"22","author":"Schwarze","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.prp.2024.155773_bib25","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13073-023-01223-1","article-title":"The clinical utility and costs of whole-genome sequencing to detect cancer susceptibility variants-a multi-site prospective cohort study","volume":"15","author":"Davidson","year":"2023","journal-title":"Genome Med"},{"key":"10.1016\/j.prp.2024.155773_bib26","doi-asserted-by":"crossref","first-page":"8375","DOI":"10.1038\/s41467-023-43732-y","article-title":"Whole-genome sequencing reveals the molecular implications of the stepwise progression of lung adenocarcinoma","volume":"14","author":"Haga","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2024.155773_bib27","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41591-023-02682-0","article-title":"Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme","volume":"30","author":"Sosinsky","year":"2024","journal-title":"Nat. Med"},{"key":"10.1016\/j.prp.2024.155773_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100452","article-title":"Whole-genome sequencing analysis of male breast cancer unveils novel structural events and potential therapeutic targets","volume":"37","author":"Assaad","year":"2024","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2024.155773_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/cells13060504","article-title":"Implementing Whole Genome Sequencing (WGS) in clinical practice: advantages, challenges, and future perspectives","volume":"13","author":"Brlek","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.prp.2024.155773_bib30","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s43018-022-00474-y","article-title":"The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations","volume":"4","author":"Villani","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.prp.2024.155773_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/science.abl9283","article-title":"Substitution mutational signatures in whole-genome-sequenced cancers in the UK population","volume":"376","author":"Degasperi","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.prp.2024.155773_bib32","article-title":"Unscrambling cancer genomes via integrated analysis of structural variation and copy number","volume":"2","author":"Shale","year":"2022","journal-title":"Cell Genom."},{"key":"10.1016\/j.prp.2024.155773_bib33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13073-021-00841-x","article-title":"ClinSV: clinical grade structural and copy number variant detection from whole genome sequencing data","volume":"13","author":"Minoche","year":"2021","journal-title":"Genome Med"},{"key":"10.1016\/j.prp.2024.155773_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.08.006","article-title":"Distinct classes of complex structural variation uncovered across thousands of cancer genome graphs","volume":"183","author":"Hadi","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.prp.2024.155773_bib35","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/PAS.0000000000002159","article-title":"NIPBL::NACC1 fusion hepatic carcinoma","volume":"48","author":"Hissong","year":"2024","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2024.155773_bib36","article-title":"Unearthed novel molecular phenotypes and potential therapeutic targets in esophagogastric adenocarcinoma","author":"Windon","year":"2024","journal-title":"medRxiv"},{"key":"10.1016\/j.prp.2024.155773_bib37","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1186\/s12864-018-5096-9","article-title":"Bead-linked transposomes enable a normalization-free workflow for NGS library preparation","volume":"19","author":"Bruinsma","year":"2018","journal-title":"BMC Genom."},{"key":"10.1016\/j.prp.2024.155773_bib38","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.225","article-title":"Use of a navigable interface for integrated whole genome and transcriptome sequencing as a platform for pursuit of therapeutic targets in advanced prostate cancers","volume":"41","author":"Nauseef","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2024.155773_bib39","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1038\/s41467-022-30233-7","article-title":"Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers","volume":"13","author":"Shukla","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2024.155773_bib40","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a006275","article-title":"The importance of escalating molecular diagnostics in patients with low-grade pediatric brain cancer","volume":"9","author":"Al Assaad","year":"2023","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"10.1016\/j.prp.2024.155773_bib41","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/PAS.0000000000002159","article-title":"NIPBL::NACC1 Fusion Hepatic Carcinoma","volume":"48","author":"Hissong","year":"2024","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2024.155773_bib42","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/PAS.0000000000002099","article-title":"Whole-genome Analysis Elucidates Complex Genomic Events in GLI1 -rearranged Enteric Tumor","volume":"47","author":"Mendelson","year":"2023","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2024.155773_bib43","article-title":"Whole genome landscape analysis of homologous recombination deficiency in a pan-cancer cohort","author":"Assaad","year":"2024","journal-title":"medRxiv"},{"key":"10.1016\/j.prp.2024.155773_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100452","article-title":"Whole-genome sequencing analysis of male breast cancer unveils novel structural events and potential therapeutic targets","author":"Al Assaad","year":"2024","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2024.155773_bib45","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-2149","article-title":"Abstract 2149: A whole genome sequencing classifier of homologous recombination deficiency","volume":"83","author":"Hadi","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2024.155773_bib46","doi-asserted-by":"crossref","first-page":"6647","DOI":"10.1158\/0008-5472.CAN-07-0924","article-title":"The ubiquitin-interacting motif containing protein RAP80 interacts with BRCA1 and functions in DNA damage repair response","volume":"67","author":"Yan","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.prp.2024.155773_bib47","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.1038\/s41598-024-56831-7","article-title":"CDK12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer","volume":"14","author":"Lu","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2024.155773_bib48","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1634\/theoncologist.2019-0214","article-title":"Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype","volume":"24","author":"Sokol","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.prp.2024.155773_bib49","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ccell.2018.07.011","article-title":"Tandem duplications may supply the missing genetic alterations in many triple-negative breast and gynecological cancers","volume":"34","author":"Rao","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.prp.2024.155773_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.820128","article-title":"Neoadjuvant treatment in ovarian cancer: New perspectives, new challenges","volume":"12","author":"Nikolaidi","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.prp.2024.155773_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.577869","article-title":"Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant","volume":"11","author":"Yang","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.prp.2024.155773_bib52","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3390\/curroncol29010022","article-title":"Neoadjuvant and adjuvant systemic therapy for newly diagnosed Stage II-IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: a practice guideline","volume":"29","author":"Hirte","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.prp.2024.155773_bib53","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/ijgc-2020-001822","article-title":"Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy","volume":"31","author":"van den Heerik","year":"2021","journal-title":"Int J. Gynecol. Cancer"},{"key":"10.1016\/j.prp.2024.155773_bib54","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ygyno.2021.06.016","article-title":"Use and outcomes of neoadjuvant chemotherapy for metastatic uterine cancer","volume":"162","author":"Wright","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.prp.2024.155773_bib55","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ygyno.2018.10.032","article-title":"Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression","volume":"152","author":"Ashley","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.prp.2024.155773_bib56","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju249","article-title":"Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer","volume":"106","author":"Konecny","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.prp.2024.155773_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15020448","article-title":"DNA damage response alterations in ovarian cancer: from molecular mechanisms to therapeutic opportunities","volume":"15","author":"Ovejero-S\u00e1nchez","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prp.2024.155773_bib58","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.prp.2024.155773_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/cells8060584","article-title":"New challenges in tumor mutation heterogeneity in advanced ovarian cancer by a targeted Next-Generation Sequencing (NGS) approach","volume":"8","author":"Garziera","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.prp.2024.155773_bib60","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ygyno.2013.06.019","article-title":"Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies","volume":"130","author":"Ross","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.prp.2024.155773_bib61","first-page":"1162","article-title":"Real-world efficacy and safety of PARP inhibitors in recurrent ovarian cancer patients with somatic BRCA and other homologous recombination gene mutations","volume":"57","author":"Pan","year":"2023","journal-title":"Ann. Pharm."},{"key":"10.1016\/j.prp.2024.155773_bib62","article-title":"Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis","volume":"7","author":"Gulia","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.prp.2024.155773_bib63","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/s12885-020-06948-5","article-title":"Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review","volume":"20","author":"Mohyuddin","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prp.2024.155773_bib64","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1158\/1078-0432.CCR-19-2933","article-title":"Routine plasma-based genotyping to comprehensively detect germline, somatic, and reversion BRCA mutations among patients with advanced solid tumors","volume":"26","author":"Vidula","year":"2020","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.prp.2024.155773_bib65","doi-asserted-by":"crossref","first-page":"181","DOI":"10.32074\/1591-951X-872","article-title":"POLE exonuclease domain mutations in endometrial carcinoma: a case report","volume":"1","author":"Pasciuto","year":"2023","journal-title":"Pathologica"},{"key":"10.1016\/j.prp.2024.155773_bib66","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1172\/JCI84940","article-title":"Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer","volume":"126","author":"Mehnert","year":"2016","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.prp.2024.155773_bib67","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.2147\/CMAR.S221001","article-title":"PARP inhibitors in endometrial cancer: current status and perspectives","volume":"12","author":"Musacchio","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.prp.2024.155773_bib68","first-page":"5830475","article-title":"A systematic review and meta-analysis on the prognostic value of BRCA mutations, homologous recombination gene mutations, and homologous recombination deficiencies in cancer","author":"Shao","year":"2022","journal-title":"J. Oncol. 2022"},{"key":"10.1016\/j.prp.2024.155773_bib69","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13048-023-01129-x","article-title":"Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma","volume":"16","author":"Feng","year":"2023","journal-title":"J. Ovarian Res"},{"key":"10.1016\/j.prp.2024.155773_bib70","article-title":"Successful treatment of stage IVB ovarian carcinosarcoma with PARP Inhibitor: A case report","volume":"51","author":"St Laurent","year":"2024","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/j.prp.2024.155773_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2018.06.008","article-title":"The Tandem Duplicator Phenotype Is a Prevalent Genome-Wide Cancer Configuration Driven by Distinct Gene Mutations","volume":"34","author":"Menghi","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.prp.2024.155773_bib72","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcad039","article-title":"CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via homologous recombination","volume":"5","author":"Brown","year":"2023","journal-title":"NAR Cancer"},{"key":"10.1016\/j.prp.2024.155773_bib73","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcaa003","article-title":"CDK12: cellular functions and therapeutic potential of versatile player in cancer","volume":"2","author":"Pilarova","year":"2020","journal-title":"NAR Cancer"},{"key":"10.1016\/j.prp.2024.155773_bib74","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cjp2.271","article-title":"Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types","volume":"8","author":"Budczies","year":"2022","journal-title":"J. Pathol. Clin. Res"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824006848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824006848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T11:32:07Z","timestamp":1739273527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033824006848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":74,"alternative-id":["S0344033824006848"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2024.155773","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing the detection of clinically relevant biomarkers in advanced uterine and tubo-ovarian carcinomas through genome-wide analysis","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2024.155773","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"155773"}}